Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Professor Matthew Costa and Dr David Metcalfe have both been awarded Hunterian Professorships for 2020 by the Royal College of Surgeons of England

Matt Costa and David Metcalfe

Named after the pioneering surgeon and scientist John Hunter and dating back over two centuries, the Hunterian Professorship is among the most highly-regarded annual awards in the field of surgery.

Matthew Costa, Professor of Orthopaedic Trauma Surgery has been awarded the Hunterian Professorship for his work on clinical trials and health economics.

Matt joined the University of Oxford in 2015 from the University of Warwick. His research interest is in clinical and cost effectiveness of musculoskeletal interventions and he is Chief Investigator for a series of randomised trials and associated studies. Cited widely, his work informs many guidelines from the National Institute for Health and Care Excellence (NICE).

Matt will deliver his Hunterian lecture entitled 'Changing Clinical Practice: latest evidence for clinical and cost-effectiveness in Trauma and Orthopaedic Surgery' at the British Orthopaedic Association (BOA) Congress in September.

David Metcalfe, Clinical Lecturer in Emergency Medicine, was also awarded a 2020 Hunterian Professorship for his work using routinely collected health data.

David was formerly a Fulbright Scholar at Harvard's Center for Surgery and Public Health and an Oxford-UCB Prize Fellow at the University of Oxford. His research interests lie in national clinical audit, health policy evaluation, evidence synthesis, and clinical risk prediction.

David's Hunterian lecture ('Improving hip fracture outcomes using routinely collected health data') builds on his DPhil, which was awarded the AOUK&I Trauma Research Prize and the Syme Medal of the Royal College of Surgeons of Edinburgh last year. His lecture will also be delivered at the BOA Congress in September.

Similar stories

£1.2M to improve diagnosis of emergency spinal condition

The National Institute for Health and Care Research has awarded an Advanced Fellowship to Dr David Metcalfe to study the diagnosis of the spinal condition, cauda equina syndrome.

Professor Chris Lavy appointed to WHO technical advisory group

Congratulations to Professor Chris Lavy, who has been appointed to the World Health Organization’s (WHO) technical advisory group for integrated clinical care for a period of two years.

Oxford receives NIHR funding to test anti-TNF on post operative delirium

Researchers at the University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) to investigate whether anti-tumour necrosis factor (TNF) therapy can reduce or prevent post operative delirium/cognitive deficit.

Gene variant links trigger finger and carpal tunnel syndrome

A new NDORMS study, published in The Lancet Rheumatology, has found a genetic variant that increases the risk of both carpal tunnel syndrome and trigger finger, and opens the door for new therapies that involve blocking the IGF-1 pathway.

Kennedy programmes support early career researchers

Since 2013 the Kennedy Institute of Rheumatology has been running a Career Development Programme, a scheme to help early career researchers launch their own independent laboratories, and more recently the Innovator Investigator Programme to bring new technologies to core research themes.

OCTRU collaboration boosts understanding of COVID vaccine response

Working with researchers across multiple universities, the Oxford Clinical Trials Unit (OCTRU) played a key role in delivering results of the national VROOM trial (Vaccine Response On Off Methotrexate).